Back to Main

Faculty Detail    
Name ANDRES FORERO-TORRES
 
Campus Address NP 2510 Zip 3300
Phone 205-934-7167
E-mail aforero@uab.edu
Other websites
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Medicine  Med - Hematology & Oncology Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  General Clinical Research Center  Ctr for Clinical & Translational Sci Professor
Center  General Clinical Research Center  Minority Health & Research Center Professor

Biographical Sketch 
1987-1988: Research Fellow, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; 1988-1991: Clinical Fellow, Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; 2000-2002 Clinical Research Training Program, NIH-sponsored (K30), University of Alabama at Birmingham, Birmingham, AL.

2000-2001: Research Assistant Professor, Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; 2001-Present: Assistant Professor, Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL;
2000-Present: Associate Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL.

2000-Present: Medical Director, Clinical Studies Shared Facility, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; 2000-2004:Co-Chairman, Clinical Trials Review Committee, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; 2004-Present: Chairman, Clinical Trials Review Committee, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; 2003-Present: Member, Cancer Committee, UAB Health System.

2003-Present: Member, Non-Hodgkin’s Lymphoma panel, National Comprehensive Cancer Network (NCCN); 2004-Present: Member, Hodgkin’s Lymphoma panel, National Comprehensive Cancer Network (NCCN).

National Award in Cancer: Best Abstract in Clinical Cancer Research; Pedraza E, Esguerra H, Forero A: Allogeneic Bone Marrow Transplantation, Colombian Experience: 1995-1997. Colombian Society of Clinical Oncology, Annual meeting, Barranquilla, Colombia, October 1997.

Henri Horoszowski Memorial Prize for the Best Orthopedic Presentation; Llinas A, Silva M, Duarte M, Ucros G, Perini G, Cerquera AM, Forero A: Chronic phosphate synoviorthesis without age restriction should be the first treatment option for chronic active hemophilic synovitis. International Congress of Hemophilia, Hague, The Netherlands, May 1998.

Outstanding Teacher 2003-2004; Division of Hematology/Oncology, Fellowship Training Program, University of Alabama at Birmingham.




Society Memberships
Organization Name Position Held Org Link
American Society of Blood and Bone Marrow Transplantation   Member   
American Society of Clinical Oncology   Member   
American Society of Hematology   Member   

Research/Clinical Interest
Title
Associate Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL.
Description
Immunotherapy and Radioimmunotherapy. Lymphomas and Breast Cancer.

Selected Publications 
Publication PUBMEDID
Forero A, Khazaeli MB, Carpenter M, Meredith R, Shen S, Thornton J, Schlom J, Albert F. LoBuglio AF: An improved monoclonal antibody design for radioimmunotherapy. Cancer, Biotherapy and Radiopharmaceuticals 18, 751-759, 2003.   
Forero A, LoBuglio AF: History of antibody therapy for non-Hodgkin’s lymphoma. Semin Oncol 30 (6 Suppl 17), 1-5, 2003.   
Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, and Meredith RF.
Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Blood, Mar 2004; 10.1182/blood-2003-09-3284. Blood 104(1): 227-236, 2004. Cover page of July 1,2004 issue.
 
 
Ojha B, Muthukrishnan A, Raman AK, Satya R, Mahone T, Forero-Torres, A. Diffuse F-18 FDG uptake in skeletal muscles secondary to chills due to sepsis: A cause for underestimation of viable tumor. Clin Nucl Med 29(9): 600-604, 2004.   
de Bono JS, Vanhove GFA, Forero A, Hammond LA, Patnaik A, Takimoto A, LoBuglio AF, Rowinsky EK, Bauer RJ, White ML, Tolcher AW: A phase I trial of an intravenously administered human-engineeredTM monoclonal anti-EpCAM antibody, ING-1 (he-Mab), in patients with advanced adenocarcinomas. Accepted for publication, Clin Cancer Res, November 15, 2004.   

Keywords
immunotherapy, radioimmunotherapy, breast cancer, lymphomas